title: Letter by Filippidis et al regarding article, "Evaluating strategies for the treatment of cerebral cavernous malformations".
authors.forename: Aristotelis S
authors.initials: AS
authors.lastname: Filippidis
authors.forename: Kostas N
authors.initials: KN
authors.lastname: Fountas
authors.forename: M Yashar S
authors.initials: MY
authors.lastname: Kalani
authors.forename: Joseph M
authors.initials: JM
authors.lastname: Zabramski
authors.forename: Robert F
authors.initials: RF
authors.lastname: Spetzler
mesh_terms: D018674:Adrenergic Antagonists / Q000627:therapeutic use; D016543:Central Nervous System Neoplasms / Q000188:drug therapy*; D020785:Central Nervous System Vascular Malformations / Q000188:drug therapy*; D020786:Hemangioma, Cavernous, Central Nervous System / Q000188:drug therapy*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D011433:Propranolol / Q000627:therapeutic use*
chemical_list: D018674:Adrenergic Antagonists; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011433:Propranolol